Cns gene delivery using peripheral administration of aav vectors
AssigneesGenethon, Centre National De La Recherche Scientifique
InventorMartine Barkats
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.
Claims14
-13. (canceled)
A method for expressing a transgene in cerebrospinal fluid secretory cells of a subject, said method comprising peripherally administering to said subject an effective amount of a single-stranded adeno-associated virus (AAV) vector comprising an AAV9 capsid and a single-stranded genome comprising said transgene.
Dependencies are inferred from the claim text.